Investors might want to bet on SESEN BIO, INC. (SESN), as it has been recently upgraded to a Zacks Rank #2 (Buy). This upgrade primarily reflects an upward trend in earnings estimates, which is one of ...

SESEN BIO, INC. (SESN) closed the most recent trading day at $0.67, moving -1.59% from the previous trading session. This move lagged the S&P 500's daily loss of 1.13%. Meanwhile, the Dow lost 1.01%, ...

SAN DIEGO--(BUSINESS WIRE)--Shareholder rights law firm Robbins LLP announces that a class action was filed on behalf of all persons and entities that purchased or otherwise acquired Sesen Bio, Inc.

OAKLAND, Calif.--(BUSINESS WIRE)--Sesen Bio, Inc. shares dropped 13% on Wednesday, August 18, 2021 after a STAT News report claimed the FDA’s recent rejection of the company’s clinical trial for its ...

Sesen Bio Inc. SESN shares traded higher Friday on anticipation of the announcement of the company's expected FDA decision. The decision was made that the company’s Biologics License Application for ...

Shares of Sesen Bio Inc. SESN were trading sharply higher following a company announcement that the FDA granted its request for a Type A Meeting to discuss the issues brought up within the complete ...

This post may contain links from our sponsors and affiliates, and Flywheel Publishing may receive compensation for actions taken through them. Sesen Bio, Inc. is a late-stage clinical company ...

(Reuters) -The U.S. drug regulator has declined to approve Sesen Bio Inc's lead therapy candidate for a type of bladder cancer, the company said on Friday, sending its shares down more than 80%. The U ...

About four months after starting its search for strategic alternatives, Sesen Bio Inc. disclosed an all-stock merger with privately held cell-therapy specialist Carisma Therapeutics Inc., a move that ...

WHY: Rosen Law Firm, a global investor rights law firm, reminds purchasers of the securities of Sesen Bio, Inc. (NASDAQ: SESN) between December 21, 2020 and August 17, 2021, inclusive (the "Class ...